Neue Tumortherapien blockieren den RAS-RAF-MEK-ERK-Signalweg und versprechen eine signifikante Verbesserung der Prognose für zahlreiche Patienten.
Eine Monotherapie mit BRAF-Inhibitoren führt sehr rasch zu Resistenzentwicklung, was den therapeutischen Wert dieser Therapie meist zeitlich limitiert.
Durch kombinierte Therapien mit BRAF- und den neu auf dem Markt befindlichen MEK-Inhibitoren lässt sich der Signalweg weitaus effizienter und nachhaltiger blockieren. Erste Daten sind äußerst vielversprechend, allerdings stehen Langzeitergebnisse noch aus.
Melden Sie sich bitte hier kostenlos und unverbindlich an, um den Inhalt vollständig einzusehen und weitere Services von www.medmedia.at zu nutzen.
Referenzen:
– Baines AT et al., Inhibition of Ras for cancer treatment: the search continues. Future Medicinal Chemistry 2011 3:1787–1808
– Baker NM, Der CJ, Cancer: Drug for an ‚undruggable‘ protein. Nature 2013; 497:577–578
– BosJL, ras Oncogenes in Human Cancer: A Review. Cancer Research 1989; 49:4682–4689
– Davies H et al., Mutations of the BRAF gene in human cancer. Nature 2002; 417:949–954
– Engelman JA et al., Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat Med 2008; 14:1351–1356
– Flaherty et al., Inhibition of Mutated, Activated BRAF in Metastatic Melanoma. New England Journal of Medicine 2010; 363:809–819
– Flaherty KT et al., Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma. New England Journal of Medicine 2012; 367:107–114
– Flaherty KT et al., Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations. New England Journal of Medicine 2012; 367:1694–1703
– Hatzivassiliou G et al., ERK Inhibition Overcomes Acquired Resistance to MEK Inhibitors. Molecular Cancer Therapeutics 2012; 11:1143–1154
– McCubrey JA et al., Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochimica et Biophysica Acta (BBA) – Molecular Cell Research 2007; 1773:1263–1284
– Nazarian R et al., Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 2010; 468:973–977
– Oberholzer PA et al., RAS Mutations Are Associated With the Development of Cutaneous Squamous Cell Tumors in Patients Treated With RAF Inhibitors. Journal of Clinical Oncology 2012; 30:316–321
– Prior IA et al., A comprehensive survey of Ras mutations in cancer. Cancer Research 2012; 72:2457–2467
– Roberts PJ, Der CJ, Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene 2007; 26:3291–3310
– Santarpia L et al., Targeting the MAPK–RAS–RAF signaling pathway in cancer therapy. Expert Opinion on Therapeutic Targets 2012; 16:103–119
– Thakur MD, Stuart DD, Molecular Pathways: Response and Resistance to BRAF and MEK Inhibitors in BRAFV600E Tumors. Clinical Cancer Research 2014; 20:1074–1080
– Yoon S, Seger R, The extracellular signal-regulated kinase: Multiple substrates regulate diverse cellular functions. Growth Factors 2006; 24:21–44
– Zhao Y, Adjei AA, The clinical development of MEK inhibitors. Nat Rev Clin Oncol 2014; 11:385–400
– Zimmermann G et al., Small molecule inhibition of the KRAS-PDE[dgr] interaction impairs oncogenic KRAS signalling. Nature 2013; 497:638–642
